These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29662861)

  • 1. Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX.
    Yoo KY; Jung SY; Hwang SH; Lee SM; Park JH; Nam HJ
    Blood Res; 2018 Mar; 53(1):41-48. PubMed ID: 29662861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
    Matsumoto T; Shima M; Takeyama M; Yoshida K; Tanaka I; Sakurai Y; Giles AR; Yoshioka A
    J Thromb Haemost; 2006 Feb; 4(2):377-84. PubMed ID: 16420569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
    Atsou S; Furlan F; Duchemin J; Ellouze S; Sourdeau É; Launois A; Roussel-Robert V; Stieltjes N; Combe S; Fontenay M; Curis E; Jourdi G
    Eur J Pharmacol; 2021 Jan; 891():173764. PubMed ID: 33249076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged α-thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R.
    Miyashita R; Shinozawa K; Inaba H; Amano K; Kinai E
    Int J Hematol; 2022 Oct; 116(4):489-499. PubMed ID: 35590009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.
    Valke LLFG; Bukkems LH; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Mathôt RAA; van Heerde WL; Schols SEM
    J Thromb Haemost; 2020 Dec; 18(12):3222-3231. PubMed ID: 32979031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V; Jouppila A; Lassila R
    Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery.
    Tse B; Nisenbaum R; Floros G; Jiwajee A; Teitel J; Sholzberg M
    J Thromb Thrombolysis; 2023 Feb; 55(2):273-281. PubMed ID: 36547766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Global Hemostatic Assays in Response to Factor VIII Inhibitors.
    Chen P; Jani J; Streiff MB; Zheng G; Kickler TS
    Clin Appl Thromb Hemost; 2019; 25():1076029619836171. PubMed ID: 30880432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring rFVIII prophylaxis dosing using global haemostasis assays.
    Al Hawaj MA; Martin EJ; Venitz J; Barrett JC; Kuhn JG; Nolte ME; Brophy DF
    Haemophilia; 2013 May; 19(3):409-14. PubMed ID: 23510278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan.
    Takeyama M; Sasai K; Matsumoto T; Furukawa S; Ogiwara K; Yada K; Onishi T; Shima M; Nogami K
    Int J Hematol; 2022 Feb; 115(2):163-172. PubMed ID: 34724152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro.
    Hasan S; Abuelkasem E; Williams B; Henderson R; Mazzeffi MA; Tanaka KA
    Br J Anaesth; 2018 Oct; 121(4):936-943. PubMed ID: 30236256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.
    Trossaërt M; Regnault V; Sigaud M; Boisseau P; Fressinaud E; Lecompte T
    J Thromb Haemost; 2008 Mar; 6(3):486-93. PubMed ID: 18047548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
    Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
    Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis.
    Shima M
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):125-31. PubMed ID: 14872433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
    Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bordet JC; Bolbos R; Brevet M; Leissinger C; Dargaud Y
    J Thromb Haemost; 2020 Mar; 18(3):584-592. PubMed ID: 31782901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Int J Hematol; 2009 Dec; 90(5):576-582. PubMed ID: 19937483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated partial thromboplastin time-based clot waveform analysis enables measurement of very low levels of factor IX activity in patients with severe hemophilia B.
    Nishiyama A; Ogiwara K; Mizumachi K; Hashimoto N; Takeyama M; Nogami K
    Int J Hematol; 2022 Nov; 116(5):778-786. PubMed ID: 35864291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials.
    Shibasaki F; Takeyama M; Ogiwara K; Furukawa S; Nakajima Y; Shimonishi N; Nogami K
    Int J Hematol; 2023 May; 117(5):669-677. PubMed ID: 36607560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.